USFDA22 Apr 2026, 08:34 am
Ajanta Pharma's Paithan facility gets 5 US FDA observations
AI Summary
Ajanta Pharma Ltd. announced that the US FDA concluded an inspection at its manufacturing facility in Paithan, Maharashtra. The inspection, conducted from April 13 to April 21, 2026, resulted in the issuance of Form-483 with five observations. The company has stated its intention to respond to the US FDA within the specified timeframe. This development is significant for investors as regulatory compliance, particularly with the US FDA, is crucial for pharmaceutical companies' operations and market access.
Key Highlights
- US FDA inspected Ajanta Pharma's Paithan facility.
- Inspection concluded with 5 Form-483 observations.
- Company will respond to US FDA within stipulated timeline.
- Regulatory compliance is key for pharma operations.